Hi <<First Name>>! - eSUN - June 2016 - Research News, Clinical Trial Participation Opportunities, and more...

Switching from a Brand Name Biologic to its ‘Biosimilar’ Ineffective in Those Who've Developed Antibodies to the Original

First what is a biosimilar? Simply put, a biosimilar is a type of biological medication that is highly similar to the original brand name medication it is simulating, known as its reference product. It has also been called a copycat version. In order to gain FDA approval, a biosimilar must demonstrate that it is “highly similar” to an already approved biological medication.

Genetics of Ankylosing Spondylitis: A Review and Update

Ankylosing spondylitis (AS) is considered a complex genetic disease, as more than one gene is involved. We know the importance and weight the HLA-B27 gene carries in AS, which is currently thought to be responsible for about 30% of the total genetic risk; however, there are numerous other “smaller effect” genes that combined play a much larger role in AS.

Distinguishing Clinical Features in Psoriatic Arthritis (Video Included)

Psoriatic arthritis is an inflammatory arthritis that occurs in people with psoriasis. We know that psoriasis occurs in about 3% of the population of the United States, and psoriatic arthritis occurs in up to 30% of people with psoriasis.

Classification of Spondyloarthritis: A Historical
Perspective (Video Included)

Historically, spondyloarthritis has been characterized into a number of different subtypes, including ankylosing spondylitis (“AS”), psoriatic arthritis, the arthritis associated with inflammatory bowel disease—something called reactive arthritis, which is triggered by an infectious agent..

Read The Article & Watch The Video >>>

Clinical Trial Opportunity for Adults Recently Diagnosed with or experiencing symptoms of Axial Spondyloarthritis

A Phase 3 clinical trial is now recruiting axial spondyloarthritis patients over the age of 18 who have been experiencing symptoms for at least 12 months.

Learn More >>>

A Multicenter, Postmarketing Study Evaluating the Transfer of Cimzia® (certolizumab pegol) From the Mother to the Infant Via the Placenta (CRIB)

The CRIB Study is a clinical research study conducted by UCB BioSciences, Inc., for women who are pregnant and receiving treatment with certolizumab pegol (Cimzia®). The purpose of the study is to determine if Cimzia® crosses from the mother through the placenta to the infant.

Click Here To Learn More >>>

Upcoming Support Group Meetings

Upcoming support group meetings include:

- Saturday, June 18, 2016 – Stamford, CT
  Click here for details >>>
- Saturday June 18, 2016 – Phoenix, AZ
  Click here for details >>>
- Tuesday, June 21, 2016 – Lansing, MI
  Click here for details >>>
- Thursday, June 23, 2016 – New York, NY
  Click here for details >>>
- Thursday, July 7, 2016 – Mission Viejo, CA
  Click here for details >>>
- Saturday, July 9, 2016 – Morristown, NJ
  Click here for details >>>
- Saturday, July 9, 2016 – The Woodlands, TX
Donate SMART

The Spondylitis Monthly Automatic Rewards Team (S.M.A.R.T.) is a safe, secure and convenient way to put more of your money to work advancing the spondylitis community’s shared mission.

By completing this transaction, you will authorize the Spondylitis Association of America to charge your credit card on a monthly basis until further notice. You may cancel this recurring transaction at any time by contacting SAA in writing or by calling SAA’s information line at 800-777-8189.

Click here to learn how you can help >>>

Please remember us in your estate planning.

This email was sent to <<Email Address>>

why did I get this? unsubscribe from this list update subscription preferences
Spondylitis Association of America · P.O. Box 5872 · Sherman Oaks, CA 91413 · USA